🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to the Babraham Investor Conference 2022 today (June 23rd). We are presenting alongside some other exciting scale-up and start-up companies in life sciences. Thanks to Babraham Research Campus! More info: lnkd.in/ehVxR2xk

RT One Nucleus: The programme for our #ONHelix22 life science conference on 7 July includes Enabling Bio Innovation, chaired by Priya Kalia of SciTribe and includes a panel from Thermo Fisher Nuclera and Semarion Find out more here ow.ly/Fks850Jy42e

Excited to be at #MilnerSymp22 today! Every year the Milner Therapeutics Institute pull together a great list of speakers and attendees from across academia and industry in an effort to push forward collaborative drug development and increase the standard of patient care.

The CEO’s of our portfolio companies Semarion and Enhanc3D Genomics are speaking at One Nucleus’ #ONHelix22 conference taking place on July 7th in #Cambridge. Find more information about this year's theme and agenda here: onhelix.com

Having studied MatSci, Rachel found a new love for biology, leading her to join Russell Cowburn, Grant Stewart, Semarion for a PhD using nano-magnets for early detection of kidney cancer. "Nano gave me the confidence to try out a new field – I’m hyped to see where it goes!"

Seasonal greetings from Semarion. We had a little little bit of fun with our cell microcarriers. Have a look at the video and enjoy our wintery story! About: A549 cells on pine shaped carriers, dancing to magenta and being dosed with mulled wine. youtu.be/C30a5-rmrT4

The Pathfinder award at the #BusinessWeeklyAwards is presented to @semarion_ltd by Aline Charpentier Bruntwood SciTech. Well done to the team #DrugDiscovery

Congratulations to Milner Therapeutics Institute Affiliate Partners who won the latest 2023 Business Weekly Awards! 🎉 Semarion won The Pathfinder Award and Domainex won The Life Science Scale-up Award. Read more at: ow.ly/mBLj50PLZjw

It is wonderful to see Semarion grow from strength to strength. We Maxwell Centre are proud to be part of your journey.

Excited at attend @ELRIG_UK Drug Discovery 2023 today. Come and see us at Booth C7. We'll be demonstrating our SemaCyte Microcarriers Platform and show how it accelerates cell assaying workflows. #DD2023

We are launching our Early Adopter Programme! Get early access to our SemaCyte Microcarrier Platform to experience how this novel approach to adherent cell assaying can supercharge your drug discovery workflows. semarion.com/semarion-annou…

📣 Semarion launches SemaCyte Microcarrier Platform! The platform addresses limitations within adherent cell assays to accelerate the pace of in vitro drug discovery. Gain early access & see how the technology can improve drug discovery workflows! lnkd.in/eUJdHNne!

WEBINAR about SemaCyte Cell Assaying Microcarriers 🧫Ultra-miniaturized, mobile wells to move and freeze cells while preserving their adherent morphology 🚀Flexibility, speed, miniaturization for cell assays 📅 November 15 | 10:00-11:00 GMT | Register: events.teams.microsoft.com/event/45ef4cff…

SemaCyte Microcarriers - Move & Freeze Adherent Cells to Accelerate Assays. Tomorrow 10-11am. Affiliate Partner Semarion is hosting this webinar to explain how their unique SemaCyte® microcarriers function can accelerate various cell-based assays. ow.ly/H9Ek50Q5x3A

Ever seen adherent cells move like this? Semarion is pushing the boundaries of what you can do with live cells! How: nextgen magnetic microcarriers. Why are we doing this? To Accelerate Cell Assays. Find our more: semarion.com #innovation #biotech #nanotechnology

#TBT #BusinessWeeklyAwards Pathfinder Award winner Semarion is revolutionising drug discovery by combining material science & cell biology. Its technology brings flexibility, miniaturisation, & multiplexing to biopharma workflows, ensuring faster & superior data generation

.Semarion introduces its SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery. The platform enables optical barcoding and pooling of adherent cells and is available through Semarion’s Early Adopter Program: rb.gy/fs9k7g

Earlier this week, we attended @ELRIG_UK's Research & Innovation 2024. It was great to catch up with the teams at Nuclera and Semarion, as well as hear from Dr Dave Chapman (Centauri Therapeutics) about the Company's novel approach to combat antibiotic resistance.

Tarun Vemulkar and Jeroen Verheyen from Semarion presenting what Semarion does and why at West Hub, Cambridge at #CWOD. We are very proud to be part of your journey at Maxwell Centre Cambridge University